Intra-Cellular Therapies, Inc. vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored

Biotech Cost Efficiency: Intra-Cellular vs. Wave Life Sciences

__timestampIntra-Cellular Therapies, Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 2014212263452395000
Thursday, January 1, 20151396269057000
Friday, January 1, 201693831530393000
Sunday, January 1, 20177941900979309000
Monday, January 1, 2018368673134428000
Tuesday, January 1, 2019477121175431000
Wednesday, January 1, 20201895029124165000
Friday, January 1, 20218034589121875000
Saturday, January 1, 20222044300010114000
Sunday, January 1, 2023337450009206000
Loading chart...

Data in motion

Exploring Cost Efficiency in Biotech: Intra-Cellular Therapies vs. Wave Life Sciences

In the dynamic world of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Intra-Cellular Therapies, Inc. and Wave Life Sciences Ltd. from 2014 to 2023. Over this period, Intra-Cellular Therapies demonstrated a significant reduction in cost of revenue, with a notable dip in 2015, where costs plummeted to a mere fraction of their 2014 levels. Conversely, Wave Life Sciences experienced a substantial increase, peaking in 2019 with costs nearly 73 times higher than in 2014. By 2023, Intra-Cellular Therapies had increased its cost efficiency, with costs rising by approximately 59% from 2022, while Wave Life Sciences saw a decrease of about 9%. This comparison highlights the contrasting strategies and market responses of these two biotech firms, offering valuable insights into their operational efficiencies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025